Marker Therapeutics, Inc.
MRKRNASDAQHealthcare● Active
$1.46
+$0.04(+2.82%)
Market Cap$15764696
P/E Ratio—
52W High$4.07
52W Low$0.81
Marker Therapeutics, Inc. (MRKR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MRKR · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.16
Est. -$0.18 · +11.1%
Revenue
$0.00B
Est. $0.00B · +2.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 5-Quarter EPS Beat Streak
MRKR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.25 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.18 | -$0.16 | +11.1% | $0.00B | $0.00B | +2.0% |
| ▲ Q1 FY2026 | Mar 18, 2026 | -$0.21 | -$0.04 | +81.0% | $0.00B | $0.00B | +61.3% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.36 | -$0.12 | +66.7% | $0.00B | $0.00B | +70.5% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.30 | -$0.29 | +4.6% | $0.00B | $0.00B | +100.0% |
| ▲ Q2 FY2025 | May 21, 2025 | -$0.66 | -$0.27 | +59.1% | $0.00B | $0.00B | +100.0% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.22 | -$0.42 | -90.9% | $0.00B | $0.00B | +84.1% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.39 | -$0.26 | +33.3% | $0.00B | $0.00B | +92.6% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.16
EPS Est.
-$0.18
EPS Surpr.
+11.1%
Revenue
$0.00B
Q1 FY2026
Mar 18, 2026Beat
EPS Actual
-$0.04
EPS Est.
-$0.21
EPS Surpr.
+81.0%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.36
EPS Surpr.
+66.7%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.29
EPS Est.
-$0.30
EPS Surpr.
+4.6%
Revenue
$0.00B
Q2 FY2025
May 21, 2025Beat
EPS Actual
-$0.27
EPS Est.
-$0.66
EPS Surpr.
+59.1%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.42
EPS Est.
-$0.22
EPS Surpr.
-90.9%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.26
EPS Est.
-$0.39
EPS Surpr.
+33.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q3 FY2027 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Q2 FY2027 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Q1 FY2027 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q4 FY2026 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q3 FY2026 | $-0.34 | $-0.27 | $-0.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +11.1% | $1.46 | $1.42 | -2.74% |
| ▲ Q1 FY2026 | Mar 18, 2026 | +81.0% | $1.36 | $1.34 | -1.47% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +66.7% | $0.94 | $0.89 | -5.47% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +4.6% | $1.29 | $1.25 | -3.10% |
| ▲ Q2 FY2025 | May 21, 2025 | +59.1% | $1.14 | $1.10 | -3.51% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -90.9% | $1.27 | $1.23 | -3.15% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +33.3% | $3.64 | $3.50 | -3.85% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +32.6% | $3.39 | $3.36 | -0.88% |
Q2 FY2026-2.74%
Report Date
May 15, 2026
EPS Beat/Miss
+11.1%
Price Before
$1.46
Price After
$1.42
Q1 FY2026-1.47%
Report Date
Mar 18, 2026
EPS Beat/Miss
+81.0%
Price Before
$1.36
Price After
$1.34
Q4 FY2025-5.47%
Report Date
Nov 13, 2025
EPS Beat/Miss
+66.7%
Price Before
$0.94
Price After
$0.89
Q3 FY2025-3.10%
Report Date
Aug 14, 2025
EPS Beat/Miss
+4.6%
Price Before
$1.29
Price After
$1.25
Q2 FY2025-3.51%
Report Date
May 21, 2025
EPS Beat/Miss
+59.1%
Price Before
$1.14
Price After
$1.10
Q1 FY2025-3.15%
Report Date
Mar 31, 2025
EPS Beat/Miss
-90.9%
Price Before
$1.27
Price After
$1.23
Q4 FY2024-3.85%
Report Date
Nov 14, 2024
EPS Beat/Miss
+33.3%
Price Before
$3.64
Price After
$3.50
Q3 FY2024-0.88%
Report Date
Aug 14, 2024
EPS Beat/Miss
+32.6%
Price Before
$3.39
Price After
$3.36
Avg Beat Reaction-3.00%
Avg Miss Reaction-3.15%
Beat Rate7 / 8 quarters
Largest Move-5.47% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MRKR ends December
Marker Therapeutics, Inc. (MRKR) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.16 — beating the analyst consensus of $-0.18 by +11.1%. MRKR has beaten EPS estimates for 5 consecutive quarters. The next MRKR earnings date is expected around September 1, 2026.
Each quarter, investors track MRKR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MRKR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MRKR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MRKR earnings · 5 questionsMarker Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. MRKR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MRKR historically reports after market close (AMC).
MRKR earnings datewhen is MRKR earningsMRKR next earnings datewhen does MRKR report earningsMRKR earnings calendar
▸ Source: FMP · Marker Therapeutics, Inc. SEC filings · US GAAP · Marker Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026